Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
26
SCYX Quote, Financials, Valuation and Earnings
Last price:
$0.62
Seasonality move
:
-4.6%
Day range:
$0.62 - $0.63
52-week range:
$0.57 - $1.49
Dividend yield:
0%
P/E ratio:
0.85x
P/S ratio:
10.00x
P/B ratio:
0.72x
Volume:
235.3K
Avg. volume:
481.4K
1-year change:
-37.92%
Market cap:
$26.3M
Revenue:
$3.7M
EPS (TTM):
-$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
|
$147.7K | -$0.20 | 729.07% | -77.15% | $3.67 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.84% | 39.23% | $110.04 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
|
$0.63 | $3.67 | $26.3M | 0.85x | $0.00 | 0% | 10.00x |
|
MRK
Merck & Co., Inc.
|
$101.09 | $110.04 | $250.9B | 13.37x | $0.85 | 3.25% | 3.99x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $722.3K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
|
5.9% | -0.714 | 7.07% | 4.49x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SCYX
SCYNEXIS, Inc.
|
-- | -$8.4M | -44.49% | -51.63% | -2516.47% | -$8.7M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
SCYNEXIS, Inc. vs. Competitors
-
Which has Higher Returns SCYX or MRK?
Merck & Co., Inc. has a net margin of -2572.16% compared to SCYNEXIS, Inc.'s net margin of 33.68%. SCYNEXIS, Inc.'s return on equity of -51.63% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital SCYXSCYNEXIS, Inc.-- -$0.17 $38.7M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About SCYX or MRK?
SCYNEXIS, Inc. has a consensus price target of $3.67, signalling upside risk potential of 484.8%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 8.85%. Given that SCYNEXIS, Inc. has higher upside potential than Merck & Co., Inc., analysts believe SCYNEXIS, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SCYXSCYNEXIS, Inc.2 0 0 MRKMerck & Co., Inc.15 12 0 -
Is SCYX or MRK More Risky?
SCYNEXIS, Inc. has a beta of 1.366, which suggesting that the stock is 36.596% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock SCYX or MRK?
SCYNEXIS, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.85 per share. SCYNEXIS, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SCYX or MRK?
SCYNEXIS, Inc. quarterly revenues are $334K, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. SCYNEXIS, Inc.'s net income of -$8.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, SCYNEXIS, Inc.'s price-to-earnings ratio is 0.85x while Merck & Co., Inc.'s PE ratio is 13.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SCYNEXIS, Inc. is 10.00x versus 3.99x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SCYXSCYNEXIS, Inc.10.00x 0.85x $334K -$8.6M MRKMerck & Co., Inc.3.99x 13.37x $17.2B $5.8B
-
Which has Higher Returns SCYX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -2572.16% compared to SCYNEXIS, Inc.'s net margin of -255.85%. SCYNEXIS, Inc.'s return on equity of -51.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SCYXSCYNEXIS, Inc.-- -$0.17 $38.7M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SCYX or NBY?
SCYNEXIS, Inc. has a consensus price target of $3.67, signalling upside risk potential of 484.8%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that SCYNEXIS, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe SCYNEXIS, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SCYXSCYNEXIS, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SCYX or NBY More Risky?
SCYNEXIS, Inc. has a beta of 1.366, which suggesting that the stock is 36.596% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SCYX or NBY?
SCYNEXIS, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. SCYNEXIS, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SCYX or NBY?
SCYNEXIS, Inc. quarterly revenues are $334K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. SCYNEXIS, Inc.'s net income of -$8.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, SCYNEXIS, Inc.'s price-to-earnings ratio is 0.85x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SCYNEXIS, Inc. is 10.00x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SCYXSCYNEXIS, Inc.10.00x 0.85x $334K -$8.6M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns SCYX or OGEN?
Oragenics, Inc. has a net margin of -2572.16% compared to SCYNEXIS, Inc.'s net margin of --. SCYNEXIS, Inc.'s return on equity of -51.63% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital SCYXSCYNEXIS, Inc.-- -$0.17 $38.7M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About SCYX or OGEN?
SCYNEXIS, Inc. has a consensus price target of $3.67, signalling upside risk potential of 484.8%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that SCYNEXIS, Inc. has higher upside potential than Oragenics, Inc., analysts believe SCYNEXIS, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SCYXSCYNEXIS, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is SCYX or OGEN More Risky?
SCYNEXIS, Inc. has a beta of 1.366, which suggesting that the stock is 36.596% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock SCYX or OGEN?
SCYNEXIS, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SCYNEXIS, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SCYX or OGEN?
SCYNEXIS, Inc. quarterly revenues are $334K, which are larger than Oragenics, Inc. quarterly revenues of --. SCYNEXIS, Inc.'s net income of -$8.6M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, SCYNEXIS, Inc.'s price-to-earnings ratio is 0.85x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SCYNEXIS, Inc. is 10.00x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SCYXSCYNEXIS, Inc.10.00x 0.85x $334K -$8.6M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns SCYX or PTN?
Palatin Technologies has a net margin of -2572.16% compared to SCYNEXIS, Inc.'s net margin of --. SCYNEXIS, Inc.'s return on equity of -51.63% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SCYXSCYNEXIS, Inc.-- -$0.17 $38.7M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SCYX or PTN?
SCYNEXIS, Inc. has a consensus price target of $3.67, signalling upside risk potential of 484.8%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than SCYNEXIS, Inc., analysts believe Palatin Technologies is more attractive than SCYNEXIS, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SCYXSCYNEXIS, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is SCYX or PTN More Risky?
SCYNEXIS, Inc. has a beta of 1.366, which suggesting that the stock is 36.596% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SCYX or PTN?
SCYNEXIS, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SCYNEXIS, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SCYX or PTN?
SCYNEXIS, Inc. quarterly revenues are $334K, which are larger than Palatin Technologies quarterly revenues of --. SCYNEXIS, Inc.'s net income of -$8.6M is higher than Palatin Technologies's net income of --. Notably, SCYNEXIS, Inc.'s price-to-earnings ratio is 0.85x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SCYNEXIS, Inc. is 10.00x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SCYXSCYNEXIS, Inc.10.00x 0.85x $334K -$8.6M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns SCYX or TOVX?
Theriva Biologics, Inc. has a net margin of -2572.16% compared to SCYNEXIS, Inc.'s net margin of --. SCYNEXIS, Inc.'s return on equity of -51.63% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital SCYXSCYNEXIS, Inc.-- -$0.17 $38.7M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About SCYX or TOVX?
SCYNEXIS, Inc. has a consensus price target of $3.67, signalling upside risk potential of 484.8%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Theriva Biologics, Inc. has higher upside potential than SCYNEXIS, Inc., analysts believe Theriva Biologics, Inc. is more attractive than SCYNEXIS, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SCYXSCYNEXIS, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is SCYX or TOVX More Risky?
SCYNEXIS, Inc. has a beta of 1.366, which suggesting that the stock is 36.596% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock SCYX or TOVX?
SCYNEXIS, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SCYNEXIS, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SCYX or TOVX?
SCYNEXIS, Inc. quarterly revenues are $334K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. SCYNEXIS, Inc.'s net income of -$8.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, SCYNEXIS, Inc.'s price-to-earnings ratio is 0.85x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SCYNEXIS, Inc. is 10.00x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SCYXSCYNEXIS, Inc.10.00x 0.85x $334K -$8.6M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
